Duration of Protection After Infant Hepatitis B Vaccination Series

BACKGROUND: Little is known about duration of protection after the infant primary series of hepatitis B (HB) vaccine in settings of low HB endemicity. This study sought to determine the proportion of adolescents immunized as infants who had protective titers of antibody to hepatitis B surface antigen (anti-HBs) before and after a challenge dose of vaccine. METHODS: US-born 16- through 19-year-olds who received a recombinant HB vaccine 3-dose series initiated within 7 days of birth (group 1) or at ≥4 weeks of age (group 2) and completed by 12 months of age were enrolled. Participants had serologic testing before and 2 weeks after randomization to receive a challenge dose of 10 µg or 20 µg of Engerix-B. Baseline and postchallenge levels of anti-HBs were compared by group, challenge dosage, and demographic and behavioral characteristics. RESULTS: At baseline, 24% had protective anti-HBs levels of ≥10 IU/mL; 92% achieved protective levels after challenge dose. Although group 1 had a lower proportion of seroprotection at baseline, group and challenge dosage were not associated with postchallenge proportion of seroprotection. Being in group 2, higher test dosage, higher baseline geometric mean titer, and nonwhite race were associated with significantly higher geometric mean titer after challenge dose. CONCLUSIONS: More than 90% of study participants immunized against HB as infants exhibited a seroprotective response to a challenge dose of vaccine. Duration of protection from the primary infant HB vaccine series extended through the adolescent years in the setting of low HB endemicity.

[1]  General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (Acip) , 2016, Pediatric Clinical Practice Guidelines & Policies.

[2]  Y. Liu,et al.  CD3Z Genetic Polymorphism in Immune Response to Hepatitis B Vaccination in Two Independent Chinese Populations , 2012, PloS one.

[3]  P. Patel,et al.  Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. , 2012, Vaccine.

[4]  J. Xing,et al.  Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. , 2011, Vaccine.

[5]  R. Vierkant,et al.  Genetic polymorphisms in host antiviral genes: Associations with humoral and cellular immunity to measles vaccine , 2011, Vaccine.

[6]  V. Pankratz,et al.  Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans. , 2011, The Journal of infectious diseases.

[7]  M. Safari,et al.  Persistence of HBV Vaccine’s Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran , 2010, Hepatitis monthly.

[8]  C. Tung,et al.  Effect of Needle Length When Immunizing Obese Adolescents With Hepatitis B Vaccine , 2010, Pediatrics.

[9]  A. Theamboonlers,et al.  Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. , 2010, Vaccine.

[10]  Thomas W. Hennessy,et al.  Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. , 2009, The Journal of infectious diseases.

[11]  S. Shrestha,et al.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth , 2009, Human Genetics.

[12]  Sheng-Nan Lu,et al.  Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. , 2009, Vaccine.

[13]  M. Pantin-Jackwood,et al.  Pathogenesis of H5N1 influenza virus infections in mice and ferret models differs according to respiratory tract or digestive system exposure. , 2009, The Journal of infectious diseases.

[14]  Ryan T Novak,et al.  Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at Birth: A 15-Year Follow-Up Study , 2008, The Pediatric infectious disease journal.

[15]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. , 2007, Vaccine.

[16]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study , 2005, The Lancet.

[17]  B. McMahon,et al.  Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy , 2005, Pediatrics.

[18]  P. De Wals,et al.  Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country , 2005, The Pediatric infectious disease journal.

[19]  B. McMahon,et al.  Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth , 2004, The Pediatric infectious disease journal.

[20]  M. S. Rezai,et al.  Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. , 2004, Indian pediatrics.

[21]  Laura Kann,et al.  Reliability of the 1999 youth risk behavior survey questionnaire. , 2002, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[22]  P. van Damme,et al.  Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. , 2000, Vaccine.

[23]  D. West,et al.  Clinical experience with hepatitis B vaccines. , 1989, American journal of infection control.

[24]  A. Aplogan,et al.  From the Centers for Disease Control and Prevention , 2015 .

[25]  T. Tumpey,et al.  Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. , 2009, Advances in virus research.

[26]  W. Gropp,et al.  Accepted for publication , 2001 .

[27]  I. Symington,et al.  Influence of smoking on immunological responses to hepatitis B vaccine. , 1994, Vaccine.